嘉和生物药业 Genor Biopharma  
嘉和生物药业有限公司成立于2007年12月，是一家创新驱动型生物制药公司，主要致力于治疗性单克隆抗体、Fc-融合蛋白药物的研发与产业化。

目前公司总投资已超过2亿人民币，员工约110人。嘉和产品线现有10余个在研产品，其中3个在研产品处于临床试验或者临床报批阶段。嘉和拥有6000 多平米的研发中心、工艺开发中心、质量分析中心和cGMP临床药品生产基地，并正在规划建设规模化的cGMP商业生产基地。

嘉和拥有一支经验丰富并且搭配完整的资深专家组成的核心团队，其成员专业经验涵盖了单抗药物研发的各个关键环节。他们都来自Amgen, Abbott等国外著名生物制药公司，均具有15~20年左右的工业界经验。

合作是嘉和公司发展策略的关键组成部分。除了内部研发以外，我们还积极寻求项目引进、合作开发以及建立合资企业等机会，以丰富公司的产品线；同时，我们也积极寻求产品输出及其他创新性合作模式的机会，以推进嘉和产品进入其他新兴市场和/或欧美市场。


Founded in December 2007, Genor Biopharma is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs.

With a total investment of about 30 million USD, Genor Biopharma now has ~ 10 products in pipeline (Three at clinical trial/IND stage), about 110 employees, and more than 6000 m2 of space including R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility. A commercial scale cGMP production facility is also under active planning.

Genor Biopharma has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15~20 years of hand-on working experience at leading western biopharmas such as Amgen, Abbott etc.

Partnership is an intrinsic part of Genor Biopharma’s coporate strategy. Besides in-house R&D we actively seek in-licensing, co-development or JV opportunities to strengthen our pipeline. In the same time, we are also actively exploring out-licensing and other creative collaboration models to help propel Genor products into other emerging markets and/or western markets.